BridgeBio Pharma, Inc. (BBIO), a company focused on genetic diseases and cancers, said on Friday that it has inked a deal with certain investors to issue and sell its 9.167 million shares at September 22 closing price of $27.27 per share through a private investment in public equity or PIPE financing.
Neil Kumar, CEO of BridgeBio, said: "Their support will help us fund our future operations, including the launch of acoramidis and our upcoming Phase 3 readouts in achondroplasia, LGMD2I, and ADH1, and will allow us to pursue additional less dilutive financing options to optimize our cost of capital…"
The drug maker expects gross proceeds of around $250 million from the transaction, which is scheduled to conclude on September 27.
The PIPE financing was led by Qatar Investment Authority, with the participation of investment management firms, institutional investors, and existing investors.
BridgeBio noted that it also continues to explore additional strategic options to fund the business.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.